--- title: "Pre-market hot trades in US stocks: Mastec up 7.85% in pre-market; Astera Labs up 4.99% in pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/294353886.md" description: "Mastec pre-market up 7.85%; Astera Labs pre-market up 4.99%; Nuwellis pre-market up 127.51%; T3 Defense pre-market up 71.25%; China Su Xuan Tang Pharmaceutical pre-market up 49.33%" datetime: "2026-07-30T11:19:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294353886.md) - [en](https://longbridge.com/en/news/294353886.md) - [zh-HK](https://longbridge.com/zh-HK/news/294353886.md) --- # Pre-market hot trades in US stocks: Mastec up 7.85% in pre-market; Astera Labs up 4.99% in pre-market **Popular Pre-Market Trades in US Stocks** Mastec is up 7.85% in pre-market trading. There are no significant recent news; trading is active with clear capital flow. Considering the sector and industry trends, the stock shows notable volatility, and the specific reasons need further observation. no\_news Astera Labs is up 4.99% in pre-market trading. Based on recent news, 1. On July 27, Astera Labs' stock price rose 1.88%, mainly due to high market expectations for its future earnings. According to Benzinga Pro data, Astera Labs' stock price at the time of release was $297.06. 2. On July 29, Astera Labs' stock price fell 7.77%, with technical indicators showing weakened buying momentum. The MACD is below the signal line, and the negative histogram indicates a decline in buying momentum, with the stock price at the time of release being $260.56. 3. On July 29, analysts had high expectations for Astera Labs' financial report on August 4, which may determine whether the stock price pullback is a buying opportunity. The market has high expectations for Astera Labs' future earnings, while technical indicators show weakened buying momentum. **Top Gainers in Pre-Market Trading for US Stocks** Nuwellis is up 127.51% in pre-market trading. Based on recent key news: 1. On July 27, Nuwellis reported a preliminary revenue growth of 14% for the second quarter of 2026, driving a significant increase in stock price. The company stated that this growth is mainly due to the commercial success of the Aquadex ultrafiltration platform. Source: Reuters 2. On July 27, Nuwellis announced a 20% year-on-year revenue growth for the first half of 2026, further boosting market confidence. Source: Public Technologies 3. On July 27, Nuwellis plans to release its complete second-quarter financial results on August 13, with optimistic market expectations. Source: Public Technologies The medical device industry is experiencing strong growth, and the market is optimistic. T3 Defense is up 71.25% in pre-market trading. Based on recent key news: 1. On July 29, T3 Defense surged 81.56% during the trading session, currently reported at $23.785. This sharp increase is mainly driven by both technical and fundamental factors. The company's completed 1-for-125 reverse stock split has compressed the float to 1.12 million shares, triggering a technical short squeeze. Additionally, the company has made operational progress in its Project 35 in the anti-drone technology field and achieved contract delivery. X S.E. Security and Defense Ltd. acquired a 16.67% stake in the company in exchange for equity in Project 35, further boosting market confidence 2. On July 30, T3 Defense's stock price rose by 88%, currently reported at $45.12. The stock exhibits characteristics of "small float + high trading volume," leading to significant price fluctuations. 3. On July 28, T3 Defense's subsidiary Industrial Techno-Logic Solutions completed the delivery of an automated composite production line to a major Israeli manufacturer, with a contract amount of $1.1 million. At the same time, the company holds a 60% stake in Project 35, further expanding its influence in the high-demand anti-drone technology sector. SEC Schedule 13D filings show that defense investor X S.E. Security and Defense Ltd. acquired 16.67% of T3 Defense's common stock. Demand in the defense technology sector is strong, and market confidence is rising. China Su Xuan Tang Pharmaceutical, pre-market up 49.33%, has no significant news recently. Trading is active, with clear capital flow. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation ### Related Stocks - [MTZ.US](https://longbridge.com/en/quote/MTZ.US.md) - [ALAB.US](https://longbridge.com/en/quote/ALAB.US.md) - [NUWE.US](https://longbridge.com/en/quote/NUWE.US.md) - [DFNS.US](https://longbridge.com/en/quote/DFNS.US.md) - [SXTC.US](https://longbridge.com/en/quote/SXTC.US.md) ## Related News & Research - [MasTec Q2 FY26 GAAP diluted EPS rises 51% to $1.65; revenue increases 23% to $4.4 billion](https://longbridge.com/en/news/294415403.md) - [MasTec Announces the Appointment of Alex Spiro to Its Board of Directors | MTZ Stock News](https://longbridge.com/en/news/294398137.md) - [Arrowstreet Capital Limited Partnership Buys 73,615 Shares of MasTec, Inc. $MTZ](https://longbridge.com/en/news/293892955.md) - [MTZ: Record Q2 revenue and backlog, with robust growth in Clean Energy & Infrastructure](https://longbridge.com/en/news/294419273.md) - [How MasTec’s Expanding US$20.33 Billion Backlog And EPS Gains At MasTec (MTZ) Has Changed Its Investment Story](https://longbridge.com/en/news/293829470.md)